Journal of Clinical Oncology, Vol 16, 670-682, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Molecular genetics of familial cutaneous melanoma

FG Haluska and FS Hodi
Massachusetts General Hospital and the Dana-Farber Cancer Institute, Boston 02114, USA.

PURPOSE: A family history of melanoma is a significant risk factor for the disease, and recently several loci that determine susceptibility to the development of melanoma have been identified. The most important of these is p16/CDKN2A. We attempted to determine the degree to which the p16/CDKN2A gene has been implicated in the development of melanoma, and to identify other genetic factors that play a role as well. METHODS: We reviewed the literature published since the isolation of p16/CDKN2A and identified 13 studies that report the status of the gene in melanoma samples and 12 reports that examine p16/CDKN2A in melanoma kindreds. We also reviewed associated studies on CDK4 and RB1 involvement in melanoma, and examined the role of p16/CDKN2A in other inherited cancers. RESULTS: The evidence strongly implicates p16/CDKN2A in determining predisposition to malignant melanoma. Overall, approximately 20% of families that have been studied show mutations in the gene. However, because of clustering of sporadic cases in families, and potentially because of technical factors, this is likely an underestimate of the proportion of the genetic predisposition for melanoma that is due to p16/CDKN2A mutation. Rare families carry a mutated CDK4 gene that is also responsible for inherited melanoma. CONCLUSION: The gene p16/CDKN2A is an important determinant of melanoma risk. A commercial test is presently available to assess the status of this locus. However, because of uncertainties regarding the interpretation of the results of p16/CDKN2A genetic testing, we do not recommend routine clinical use of this test at this time.

This article has been cited by other articles:

				K. S.M. Smalley, R. Contractor, N. K. Haass, A. N. Kulp, G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, K. T. Flaherty, M. S. Soengas, E. Meggers, et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells Cancer Res., January 1, 2007; 67(1): 209 - 217. [Abstract] [Full Text] [PDF]

				L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]

				F. S. Hodi Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage Clin. Cancer Res., February 1, 2006; 12(3): 673 - 678. [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				P. Sarkar-Agrawal, I. Vergilis, N. E. Sharpless, R. A. DePinho, and T. M. Runger Impaired Processing of DNA Photoproducts and Ultraviolet Hypermutability With Loss of p16INK4a or p19ARF J Natl Cancer Inst, December 1, 2004; 96(23): 1790 - 1793. [Abstract] [Full Text] [PDF]

				M. Casula, M. Colombino, M. P. Satta, A. Cossu, P. A. Ascierto, G. Bianchi-Scarra, D. Castiglia, M. Budroni, C. Rozzo, A. Manca, et al. BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study J. Clin. Oncol., January 15, 2004; 22(2): 286 - 292. [Abstract] [Full Text] [PDF]

				B. D. Yu, M. Becker-Hapak, E. L. Snyder, M. Vooijs, C. Denicourt, and S. F. Dowdy Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival PNAS, December 9, 2003; 100(25): 14881 - 14886. [Abstract] [Full Text] [PDF]

				M. Eskandarpour, J. Hashemi, L. Kanter, U. Ringborg, A. Platz, and J. Hansson Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations J Natl Cancer Inst, June 4, 2003; 95(11): 790 - 798. [Abstract] [Full Text] [PDF]

				T Papp, H Pemsel, I Rollwitz, H Schipper, D G Weiss, D Schiffmann, and R Zimmermann Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi J. Med. Genet., February 1, 2003; 40(2): e14 - 14. [Full Text] [PDF]

				M.-F. Demierre and L. Nathanson Chemoprevention of Melanoma: An Unexplored Strategy J. Clin. Oncol., January 1, 2003; 21(1): 158 - 165. [Abstract] [Full Text] [PDF]

				I. Orlow, P. Roy, A. Barz, R. Canchola, Y. Song, and M. Berwick Validation of Denaturing High Performance Liquid Chromatography as a Rapid Detection Method for the Identification of Human INK4A Gene Mutations J. Mol. Diagn., November 1, 2001; 3(4): 158 - 163. [Abstract] [Full Text] [PDF]

				D. Polsky, B. C. Bastian, C. Hazan, K. Melzer, J. Pack, A. Houghton, K. Busam, C. Cordon-Cardo, and I. Osman HDM2 Protein Overexpression, but not Gene Amplification, is Related to Tumorigenesis of Cutaneous Melanoma Cancer Res., October 1, 2001; 61(20): 7642 - 7646. [Abstract] [Full Text] [PDF]

				B. Taback, Y. Fujiwara, H.-J. Wang, L. J. Foshag, D. L. Morton, and D. S. B. Hoon Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients Cancer Res., August 1, 2001; 61(15): 5723 - 5726. [Abstract] [Full Text] [PDF]

				T. Nakayama, B. Taback, R. Turner, D. L. Morton, and D. S. B. Hoon Molecular Clonality of In-Transit Melanoma Metastasis Am. J. Pathol., April 1, 2001; 158(4): 1371 - 1378. [Abstract] [Full Text] [PDF]

				J. Hashemi, A. Platz, T. Ueno, U. Stierner, U. Ringborg, and J. Hansson CDKN2A Germ-line Mutations in Individuals with Multiple Cutaneous Melanomas Cancer Res., December 1, 2000; 60(24): 6864 - 6867. [Abstract] [Full Text]

				A. D. Singh, C. L. Shields, J. A. Shields, and T. Sato Uveal Melanoma in Young Patients Arch Ophthalmol, July 1, 2000; 118(7): 918 - 923. [Abstract] [Full Text] [PDF]

				H. Tsao, X. Zhang, K. Fowlkes, and F. G. Haluska Relative Reciprocity of NRAS and PTEN/MMAC1 Alterations in Cutaneous Melanoma Cell Lines Cancer Res., April 1, 2000; 60(7): 1800 - 1804. [Abstract] [Full Text]

				T. Papp, H. Pemsel, R. Zimmermann, R. Bastrop, D. G Weiss, and D. Schiffmann Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi J. Med. Genet., August 1, 1999; 36(8): 610 - 614. [Abstract] [Full Text]

				J.-J. Grob Multiple Primary Melanoma Is Not a Distinct Biological Entity Arch Dermatol, March 1, 1999; 135(3): 325 - 327. [Full Text] [PDF]

				L. Chin, G. Merlino, and R. A. DePinho Malignant melanoma: modern black plague and genetic black box Genes & Dev., November 15, 1998; 12(22): 3467 - 3481. [Full Text]

				B. E. Clurman and M. Groudine The CDKN2A Tumor-Suppressor Locus -- A Tale of Two Proteins N. Engl. J. Med., March 26, 1998; 338(13): 910 - 912. [Full Text]